In a boost for India's nationwide COVID-19 vaccination drive, Hyderabad based Bharat Biotech which manufactures Covaxin is set to more than double the monthly production capacity by July from present five million doses to 12 million doses, reports Economic Times.
Having recently secured the necessary approvals from the authorities, the company is soon set to begin the bulk manufacturing of Covaxin at its new facility in Karnataka's capital city of Bengaluru. Dr Krishna Ella led company is also said to be engaging with other companies to further boost the production of Covaxin.
Meanwhile, Adar Poonawalla led Serum Institute of India (SII) is also expected to boost the production of Covishield to 110 million doses per month from June. This would come as a big boost as the present capacity for SII stands at 60-70 million doses per month.
Other than this, it is expected that India will soon also approve the use of the Russian Sputnik V vaccine which will further boost the availability of vaccine supplies in the nation. It is expected that the initial doses of the vaccine will be imported from Russia following which domestic production would begin.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.